Paclitaxel + Gemcitabine admixture

Phase 3Small molecule

Paclitaxel + Gemcitabine admixture is one of 7 small molecule programs targeting Pancreatic cysts. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CystsActive, not recruiting

Pancreatic CystsPhase 3

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Pancreatic Cysts

#DrugCompanyPhaseTrials

Ethanol

Roche

Phase 3

2 2

Alcohol

Astellas

Phase 2

—3

Paclitaxel + Gemcitabine admixture

MMilton S. Hershey Medical Center

Phase 3

1 4

Taxol

Cipro

Hyperpolarized 13-C-Pyruvate

MM.D. Anderson Cancer Center

Phase 1

1 7

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pancreatic cysts1 trial

CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts

Active, not recruiting·MMilton S. Hershey Medical Center·Phase 3·NCT03085004·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Paclitaxel + Gemcitabine admixture. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Paclitaxel + Gemcitabine admixture compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Paclitaxel + Gemcitabine admixture. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Milton S. Hershey Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMilton S. Hershey Medical Center

Paclitaxel + Gemcitabine admixture

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pancreatic cysts1 trial

References

Drug Info

Quick Facts

Related News